Key Figures

(as of 31 March 2022)

Staff 145
Products in development 14
Partnered products 5
Clinical readouts in 2022 7
Clinical study initiations in 2022 3
Cash for operations CHF 173.8 million
Fully financed until Q1 2024
Debt None
Shares outstanding 83.5 million
Total funds raised from investors CHF 353.6 million
Total funds received from partnering CHF 334 million
Potential total milestones from partners CHF 3.3 billion